Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, ...

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...

Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.

Shares of Sarepta Therapeutics declined 26% to $16.17 in premarket trading on Friday on media reports of a patient death after receiving one of the company's gene therapies, making it the third such ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Sanofi today and set a price target of EUR100.00. The company’s shares closed last Wednesday at $95.89. According to TipRanks.com, ...

Shares of Sarepta Therapeutics declined 16.5% in premarket trading on Friday after a Bloomberg report that a trial patient who received an experimental gene therapy has died from liver failure, making ...

Sarepta Therapeutics shares plunged premarket on Friday after the company disclosed another patient death linked to its gene therapy programs, this time during an early-stage trial for limb-girdle ...

Shares of Sarepta Therapeutics plummeted nearly 30% premarket Friday following a report that a third patient has died during ...

Intellia Therapeutics plunged 29% on safety concerns but rebounded as the full story emerged, showing the value of patience.

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...

Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The biopharmaceutical company announced a strategic restructuring plan, laying off about 500 ...

Chevron (NYSE: CVX) stock rose 3.1% after CNBC reported that the oil major has triumphed in a mediation case against rival ...